We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04453852




Registration number
NCT04453852
Ethics application status
Date submitted
3/06/2020
Date registered
1/07/2020
Date last updated
6/05/2021

Titles & IDs
Public title
Monovalent Recombinant COVID19 Vaccine
Scientific title
A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects
Secondary ID [1] 0 0
13110
Universal Trial Number (UTN)
Trial acronym
COVAX19
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coronavirus Infection 0 0
COVID 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - COVID19 vaccine
Other interventions - Saline

Experimental: Group A - Spike antigen (25ug) + 15 mg Advax-2 adjuvant

Placebo Comparator: Group B - Saline


Other interventions: COVID19 vaccine
COVID19 recombinant spike protein with Advax-SM adjuvant

Other interventions: Saline
Saline control

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Adverse Events - Incidence of Adverse Events 1 week post immunisation
Timepoint [1] 0 0
1 weeks post immunisation
Primary outcome [2] 0 0
COVID19 antibody titers - COVID19 antibody titers post immunisation
Timepoint [2] 0 0
2 weeks post second immunisation
Primary outcome [3] 0 0
COVID19 T cell immunogenicity - Frequency of COVID19 spike specific T cells 1-3 weeks post second immunisation
Timepoint [3] 0 0
3 weeks post second immunisation

Eligibility
Key inclusion criteria
Inclusion criteria

- Subjects eligible to participate in this trial had to meet all of the following
inclusion criteria:

- Provide written informed consent prior to initiation of any study procedures.

- Healthy males or non-pregnant females, aged 18 years to 65 years inclusive.

- Women of childbearing potential2 must use an acceptable contraception method3 from at
least 30 days before study vaccination until 90 days after study vaccination.

2Not sterilized via, bilateral oophorectomy, salpingectomy, hysterectomy, (permanent,
non-surgical, non-hormonal sterilization) with documented radiological confirmation
test at least 90 days after the procedure, and still menstruating or <1 year has
passed since the last menses if menopausal.

3Includes full abstinence from sexual intercourse with a male partner, monogamous
relationship with vasectomized partner who has been vasectomized for 180 days or more
barrier methods such as condoms, effective intrauterine devices, tubal ligation, and
approved hormonal methods such as implants, injectables or oral contraceptives ("the
pill").

- Women of childbearing potential must have a negative urine or serum pregnancy test
within 24 hours prior to study vaccination

- Are able to understand and comply with planned study procedures and be available for
all study visits.
Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion criteria

- • Have an acute illness, as determined by the site Principal Investigator (PI) or
appropriate sub-investigator, within 72 hours prior to study vaccination.

- Have a history of documented COVID-19 infection or a known positive COVID-19 antibody
test.

- Liver function tests (ALT, AST or GGT) > 2 times upper limit of normal

- eGFR <55 mL/min/1.73 m2

- Have immunosuppression as a result of an underlying illness or treatment, a recent
history or current use of immunosuppressive or immunomodulating disease therapy.

- Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior
to study vaccination.

- Have known active or recently active (12 months) neoplastic disease or a history of
any hematologic malignancy.

- Have known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.

- Have a history of severe systemic reactions following previous immunization with
licensed or unlicensed vaccines.

- Have a history of Guillain-Barré Syndrome.

- Have known hypersensitivity or allergy to insect stings or other components of the
study vaccine.

- Have a history of epilepsy or febrile convulsions

- Have a history of Potentially Immune-Mediated Medical Conditions (PIMMCs).

- Have a history of alcohol or drug abuse within 5 years prior to study vaccination.

- Have any diagnosis, current or past, of schizophrenia, bipolar disease or other
psychiatric diagnosis that may interfere with subject compliance or safety evaluations
as determined by the site PI or appropriate sub-investigator.

- Have been hospitalized for psychiatric illness, history of suicide attempt, or
confinement for danger to self or others within 5 years prior to study vaccination.

- Have taken oral or parenteral (including intra-articular) corticosteroids of any dose
within 30 days prior to study vaccination.

- Have taken high-dose inhaled corticosteroids within 30 days prior to study
vaccination.

- Female participants who are breastfeeding or plan to breastfeed from the time of the
first study vaccination through 30 days after the last study vaccination.

- Positive urine or serum pregnancy test within 24 hours prior to any study vaccination

- Received an experimental agent within 30 days prior to the study vaccination or expect
to receive another experimental agent during the trial-reporting period.

- Have any medical disease or condition that, in the opinion of the Investigator, is a
contraindication to study participation.

- Have any medical disease or condition that, in the opinion of the site PI or
appropriate sub-investigator, is a contraindication to study participation. *Including
acute, subacute, intermittent or chronic medical disease or condition that would place
the subject at an unacceptable risk of injury, render the subject unable to meet the
requirements of the protocol, or may interfere with the evaluation of responses or the
subject's successful completion of this trial.

- Any participant whose enrolment, in the opinion of the investigator, would be
detrimental to the participant or the study.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
PARC, - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vaxine Pty Ltd
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Central Adelaide Local Health Network Incorporated
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially
deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date,
SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three
hundred thousand people.
Trial website
https://clinicaltrials.gov/show/NCT04453852
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
David Gordon, MBBS, Ph.D
Address 0 0
CALHN
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications